We have located links that may give you full text access.
Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.
Expert Review of Anti-infective Therapy 2023 Februrary 18
INTRODUCTION: Acute bacterial skin and skin structure infections (ABSSSI) are a subtype of skin and soft tissue infections (SSTI), usually sustained by Gram-positive bacteria, whose incidence is high among children. ABSSSI are responsible for a considerable number of hospitalizations. Moreover, as multidrug resistant (MDR) pathogens become widespread, the pediatric category seems burdened with an increased risk of resistance and treatment failure.
AREAS COVERED: To obtain a view on the status of the field, we described the clinical, epidemiological, and microbiological aspects of ABSSSI in children. Old and new treatment options were critically revised with focus on the pharmacological characteristics of dalbavancin. The evidence on the use of dalbavancin in children was collected, analyzed, and summarized.
EXPERT OPINION: Many of the therapeutic options available at the moment are characterized by need for hospitalization or repeated intravenous infusion, safety issues, possible drug-drug interactions and reduced efficacy on MDRs. Dalbavancin, the first long-acting molecule with strong activity against methicillin-resistant and also many vancomycin-resistant pathogens, represented a game changer for adult ABSSSI. In pediatric settings the available literature is still limited but a growing body of evidence supports dalbavancin use in children with ABSSSI, demonstrating this drug to be safe and highly efficacious.
AREAS COVERED: To obtain a view on the status of the field, we described the clinical, epidemiological, and microbiological aspects of ABSSSI in children. Old and new treatment options were critically revised with focus on the pharmacological characteristics of dalbavancin. The evidence on the use of dalbavancin in children was collected, analyzed, and summarized.
EXPERT OPINION: Many of the therapeutic options available at the moment are characterized by need for hospitalization or repeated intravenous infusion, safety issues, possible drug-drug interactions and reduced efficacy on MDRs. Dalbavancin, the first long-acting molecule with strong activity against methicillin-resistant and also many vancomycin-resistant pathogens, represented a game changer for adult ABSSSI. In pediatric settings the available literature is still limited but a growing body of evidence supports dalbavancin use in children with ABSSSI, demonstrating this drug to be safe and highly efficacious.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app